SCHEMBL6658095

SCHEMBL6658095

FC(F)(F)c1cccc(-c2ccc3c(ccn3-c3cccnc3)c2)c1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NR3C1 P04150 1/20 0.50
PGR P06401 1/20 0.50
GRIN2B Q13224 5/20 0.44
CYP11B1 P15538 3/20 0.44
CYP11B2 P19099 3/20 0.44
NPY5R Q15761 1/20 0.44
GRIN1 Q05586 4/20 0.44
KIT P10721 3/20 0.44
HTR2B P41595 1/20 0.42
HTR6 P50406 1/20 0.42
KIF11 P52732 1/20 0.42
KDM4E B2RXH2 1/20 0.41
POLB P06746 1/20 0.41
ABL1 P00519 1/20 0.41
LCK P06239 1/20 0.41
SRC P12931 1/20 0.41
PDGFRA P16234 1/20 0.41
PIM1 P11309 1/20 0.41
DGAT1 O75907 1/20 0.40
KCNH2 Q12809 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6847487 0.90 CYP11B2 (0.43) NR3C1PGRCYP11B1CYP11B2NPY5R
SCHEMBL6846125 0.84 CYP11B2 (0.59) CYP11B1CYP11B2
SCHEMBL6657585 0.84 CYP11B2 (0.48) GRIN2BCYP11B1CYP11B2GRIN1
SCHEMBL6655119 0.83 CYP11B2 (0.51) NR3C1CYP11B1CYP11B2HTR6
SCHEMBL6657591 0.82 CYP11B2 (0.56) CYP11B1CYP11B2PIM1
SCHEMBL6656915 0.81 CYP11B1 (0.50) NR3C1GRIN2BCYP11B1CYP11B2NPY5R
SCHEMBL6657580 0.81 ROCK2 (0.48) GRIN2BCYP11B1CYP11B2NPY5RGRIN1
SCHEMBL6656090 0.81 CYP11B2 (0.50) NR3C1PGRCYP11B1CYP11B2KCNH2
SCHEMBL22515748 0.81 CYP11B2 (0.49) NR3C1CYP11B1CYP11B2HTR6
SCHEMBL6846113 0.80 CYP11B2 (0.48) CYP11B1CYP11B2HTR6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040236110-A1 Substituted 3-pyridyl indoles and indazoles as c17,20 lyase inhibitors BAYER PHARMACEUTICALS CORPORATION 2004-11-25 US disclosed
EP-1432698-A2 SUBSTITUTED 3-PYRIDYL INDOLES AND INDAZOLES AS C17,20 LYASE INHIBITORS Bayer Pharmaceuticals Corporation (US) 2004-06-30 EP disclosed
WO-2003027094-A2 SUBSTITUTED 3-PYRIDYL INDOLES AND INDAZOLES AS C17,20 LYASE INHIBITORS BAYER PHARMACEUTICALS CORPORATION (US) 2003-04-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040236110-A1 Substituted 3-pyridyl indoles and indazoles as c17,20 lyase inhibitors CYP17A1, IDO1, CYP21A2 NR3C1 2336/4885PGR 511/4885GRIN2B 4156/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.